G
Georgirene D. Vladutiu
Researcher at University at Buffalo
Publications - 89
Citations - 4255
Georgirene D. Vladutiu is an academic researcher from University at Buffalo. The author has contributed to research in topics: Myopathy & Carnitine palmitoyltransferase II. The author has an hindex of 27, co-authored 88 publications receiving 3840 citations. Previous affiliations of Georgirene D. Vladutiu include State University of New York System & Kaleida Health.
Papers
More filters
Journal ArticleDOI
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Erik S.G. Stroes,Paul D. Thompson,Alberto Corsini,Georgirene D. Vladutiu,Frederick J. Raal,Kausik K. Ray,Michael Roden,Evan A. Stein,Lale Tokgozoglu,Børge G. Nordestgaard,Eric Bruckert,Guy De Backer,Ronald M. Krauss,Ulrich Laufs,Raul D. Santos,Robert A. Hegele,G. Kees Hovingh,Lawrence A. Leiter,François Mach,Winfried März,Connie B. Newman,Olov Wiklund,Terry A. Jacobson,Alberico L. Catapano,M. John Chapman,Henry N. Ginsberg +25 more
TL;DR: The Panel proposes to identify SAMS by symptoms typical of statin myalgia and their temporal association with discontinuation and response to repetitive statin re-challenge, and recommends the use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to attain recommended low-density lipoprotein cholesterol targets.
Journal ArticleDOI
Statin-associated myopathy with normal creatine kinase levels.
Paul S. Phillips,Richard H. Haas,Sergei Bannykh,Stephanie Hathaway,Nancy L Gray,Bruce J. Kimura,Georgirene D. Vladutiu,John D.F. England +7 more
TL;DR: It appears that muscle symptoms of some patients receiving statin therapy might represent a muscle toxicity below the threshold needed to increase creatine kinase levels, which could rule out statin-associated myopathy in patients with muscle symptoms.
Journal ArticleDOI
Clinical Spectrum, Morbidity, and Mortality in 113 Pediatric Patients with Mitochondrial Disease
Fernando Scaglia,Jeffrey A. Towbin,Jeffrey A. Towbin,William J. Craigen,William J. Craigen,John W. Belmont,John W. Belmont,E. O'Brian Smith,Stephen R. Neish,Stephen R. Neish,Stephanie M. Ware,Stephanie M. Ware,Jill V. Hunter,Jill V. Hunter,Susan D. Fernbach,Susan D. Fernbach,Georgirene D. Vladutiu,Lee-Jun C. Wong,Hannes Vogel +18 more
TL;DR: This study gives strong support to the view that in patients with RC defects, cardiomyopathy is more common than previously thought and tends to follow a different and more severe clinical course.
Journal ArticleDOI
Genetic risk factors associated with lipid‐lowering drug‐induced myopathies
Georgirene D. Vladutiu,Zachary Simmons,Zachary Simmons,Paul J. Isackson,Paul J. Isackson,Mark A. Tarnopolsky,Mark A. Tarnopolsky,Wendy Peltier,Wendy Peltier,Alexandru Barboi,Alexandru Barboi,Naganand Sripathi,Naganand Sripathi,Robert L. Wortmann,Robert L. Wortmann,Paul S. Phillips,Paul S. Phillips +16 more
TL;DR: A higher prevalence of underlying metabolic muscle diseases than expected in the general population is reported and the effect of statins on energy metabolism combined with a genetic susceptibility to triggering of muscle symptoms may account for myopathic outcomes in certain high‐risk groups.
Journal ArticleDOI
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
François Mach,Kausik K. Ray,Olov Wiklund,Olov Wiklund,Alberto Corsini,Alberico L. Catapano,Eric Bruckert,Guy De Backer,Robert A. Hegele,G. Kees Hovingh,Terry A. Jacobson,Ronald M. Krauss,Ulrich Laufs,Lawrence A. Leiter,Winfried März,Winfried März,Børge G. Nordestgaard,Børge G. Nordestgaard,Frederick J. Raal,Michael Roden,Raul D. Santos,Evan A. Stein,Erik S.G. Stroes,Paul D. Thompson,Lale Tokgozoglu,Georgirene D. Vladutiu,Baris Gencer,Jane K Stock,Henry N. Ginsberg,M. John Chapman +29 more
TL;DR: Long-term statin treatment is remarkably safe with a low risk of clinically relevant adverse effects as defined above, and the established cardiovascular benefits of statin therapy far outweigh the risk of adverse effects.